SPECIAL NOTICE
We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
Computershare, Level 3, 60 Carrington Street, Sydney NSW 2000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)the suspension of trading in the securities of Pharmaxis Ltd (the "Company") will be lifted immediately, following receipt of an announcement regarding Bronchitol | 24/10/2011 |
Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add?on therapy to best standard of care." | 24/10/2011 |
company expects to receive definitive notification of the outcome of the reexamination of Bronchitol for the treatment of cystic fibrosis from the European Committee for Medicinal Products for Human Use on the evening of Friday 21 October 2011 (Australian time). The Company therefore anticipates making an announcement concerning the reexamination by 8.30am Monday 24 October 2011. That announcement will have the effect of ending the current voluntary suspension of the Company's shares | 21/10/2011 |
the securities of Pharmaxis Ltd (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement | 20/10/2011 |
the suspension of trading in the securities of Pharmaxis Ltd (the "Company") will be lifted immediately, following receipt of an announcement regarding Bronchitol | 24/10/2011 |
Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add?on therapy to best standard of care." | 24/10/2011 |
company expects to receive definitive notification of the outcome of the reexamination of Bronchitol for the treatment of cystic fibrosis from the European Committee for Medicinal Products for Human Use on the evening of Friday 21 October 2011 (Australian time). The Company therefore anticipates making an announcement concerning the reexamination by 8.30am Monday 24 October 2011. That announcement will have the effect of ending the current voluntary suspension of the Company's shares | 21/10/2011 |
the securities of Pharmaxis Ltd (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement | 20/10/2011 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 02/12/2016 | Malcolm McComas | 200,000 | $0.271 | $54,167 |
| 29/09/2016 | Gary Phillips | -400,000 | $0.277 | $110,636 |
| 29/10/2013 | Simon Buckingham | 200,000 | $0.124 | $24,854 |
| 02/05/2013 | Gary Phillips | 60,000 | $0.155 | $9,300 |
| 28/03/2013 | Richard van den Broek | 300,000 | $0.322 | $96,570 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Malcolm McComas | Non Exec Chairman, Independent Director | 07/04/2003 |
| Gary Phillips | CEO, Executive Director | 12/03/2013 |
| David McGarvey | CFO, Company Secretary | 01/12/2002 |
| Will Delaat | Independent Director | 23/06/2008 |
| Kathleen Metters | Non Exec Director | 07/06/2017 |
| Neil Graham | Non Exec Director | 04/05/2020 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Edward Rayner | Non Exec Director | 17/09/2018 | 14/08/2020 |
| Simon Buckingham | Independent Director | 25/07/2012 | 22/11/2018 |
| Richard van den Broek | Director | 07/04/2009 | 19/09/2013 |
| John Villiger | Director | 15/11/2006 | 19/09/2013 |
| Alan Robertson | CEO, Director | 25/07/2000 | 12/03/2013 |
| Denis Hanley | Chairman, Independent Director | 24/10/2001 | 01/05/2012 |
| Peter Farrell | Independent Director | 16/03/2006 | 21/10/2009 |
| Charles Kiefel | Non Exec Director | 19/12/2007 | |
| Brigitte Smith | Non Exec Director | 26/10/2006 | |
| Carrie Hillyard | Non Exec Director | 11/04/2006 | |
| Brett Charlton | Executive | 20/03/2006 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2020 Investogain Pty Limited. All rights reserved.
